Harbor Capital Advisors Inc. Reduces Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Harbor Capital Advisors Inc. trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 73.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 456 shares of the biotechnology company’s stock after selling 1,250 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Sarepta Therapeutics were worth $29,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Manchester Capital Management LLC grew its holdings in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares in the last quarter. Steward Partners Investment Advisory LLC grew its holdings in Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 194 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in Sarepta Therapeutics by 95.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 216 shares in the last quarter. Logan Capital Management Inc. purchased a new stake in Sarepta Therapeutics in the 4th quarter valued at $61,000. Finally, Jones Financial Companies Lllp grew its holdings in Sarepta Therapeutics by 274.5% in the 4th quarter. Jones Financial Companies Lllp now owns 528 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 387 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on SRPT. JPMorgan Chase & Co. decreased their price target on Sarepta Therapeutics from $169.00 to $84.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 20th. Scotiabank raised Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price target on the stock in a research note on Friday, June 6th. The Goldman Sachs Group decreased their price target on Sarepta Therapeutics from $178.00 to $100.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Bank of America reaffirmed a “neutral” rating and issued a $28.00 price target (down previously from $76.00) on shares of Sarepta Therapeutics in a research note on Monday. Finally, Jefferies Financial Group decreased their price target on Sarepta Therapeutics from $125.00 to $54.00 and set a “buy” rating on the stock in a research note on Monday. One research analyst has rated the stock with a sell rating, nine have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $99.35.

Sarepta Therapeutics Trading Down 42.1%

SRPT opened at $20.94 on Tuesday. The business’s 50-day simple moving average is $45.69 and its 200-day simple moving average is $85.25. The company has a market cap of $2.06 billion, a P/E ratio of 16.75 and a beta of 0.61. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a one year low of $18.30 and a one year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company had revenue of $744.86 million during the quarter, compared to analysts’ expectations of $685.75 million. During the same quarter last year, the business posted $0.73 earnings per share. The company’s revenue for the quarter was up 80.2% compared to the same quarter last year. As a group, equities research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.